logo-loader
viewCircassia Group PLC

Circassia Pharma Plc - Grant of options

RNS Number : 6694L
Circassia Pharmaceuticals Plc
01 May 2020
 

Grant of options

Oxford, UK - 1 May 2020: Circassia Group plc ("Circassia" or "the Company"; LSE: CIR), a specialty biopharmaceutical company focused on respiratory disease, announces that it has today granted 6,806,199 nominal and nil-cost cost options ("Options") over new ordinary shares in the Company ("Ordinary Shares") to the Executive Directors under the 2019 Performance Share Plan.

 

Name

Price per Ordinary Share

Number of shares subject to award

Michael Roller

Nil

4,000,000

Ian Johnson

Nil

1,677,233

Jonathan Emms

0.08p

1,128,966

 

The Options will vest on the third anniversary of the date of grant and are exercisable until the tenth anniversary of the date of grant. Vesting is subject to either the price of an Ordinary Share reaching 62.4p for at least 30 consecutive dealing days or a liquidity event occurring above this level.

Contacts

 

Circassia

Ian Johnson, Executive Chairman

Michael Roller, Chief Financial Officer

c/o Peel Hunt

 

Peel Hunt (Nominated Adviser and Joint Broker)

James Steel / Oliver Jackson

 

Tel: +44 (0) 20 7418 8900

 

finnCap (Joint Broker)

Geoff Nash / Alice Lane

Tel: +44 (0) 20 7220 0500

Numis Securities (Joint Broker)

James Black / Freddie Barnfield

 

Tel: +44 (0) 20 7260 1000

 

 

 

 



 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1.        

Details of the person discharging managerial responsibilities / person closely associated

a.         

Name

Ian Johnson

Michael Roller

Jonathan Emms

2.         

Reason for the notification

a.         

Position/status

Executive Chairman

Chief Financial Officer

Chief Operating Officer

b.         

Initial notification

/Amendment

 

Initial notification

3.         

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.        

Name

Circassia Group plc

b.        

LEI

2138006YAT138TOGA556

4.         

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.         

Description of the

Financial instrument, type of instrument

Identification code

Options over Ordinary shares of 0.08p each.

 

 

GB00BJVD3B28 ISIN for the Ordinary shares

b.         

Nature of the transaction

Award of share options granted under the 2019 Performance Share Plan over Ordinary Shares in Circassia

 

c.         

Price(s) and volume(s)

Price(s)

 

Volume(s)

nil

4,000,000

nil

1,677,233

0.08p

1,128,966

      

d.         

Aggregated information

·      Aggregated volume

·      Price

 

 

 

n/a

 

e.         

Date of the transaction

1 May 2020

f.         

Place of the transaction

Outside a trading venue

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
DSHGZGGKGMKGGZM

Quick facts: Circassia Group PLC

Price: 25.55

Market: LSE
Market Cap: £96.3 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Circassia Pharmaceuticals' commercial development...

Circassia Pharmaceuticals PLC's (LON:CIR) CEO Steve Harris tells Proactive London's Andrew Scott they saw strong growth in the first half of the year alongside a reduction in costs and cash outflows. Revenues for the six months ended June 30 were up 40% year-on-year at £27.9mln, with the...

on 26/9/19